Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neurescue

Explore full profile

Developing cardiovascular devices to help emergency patients

Copenhagen, DenmarkFounded 2014Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2024
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Neurescue and the history behind them.

About Neurescue

NEURESCUE is a pioneering medical device startup that has developed the first computer-aided aortic occlusion catheter. This innovative device is designed to assist in emergency medical situations, specifically during non-traumatic cardiac arrest. The primary function of the NEURESCUE device is to temporarily block the aorta, the main artery in the body, to increase blood flow to the heart and brain during cardiopulmonary resuscitation (CPR). This process, known as Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA), can significantly improve the chances of resuscitation and protect the brain from damage due to lack of blood flow.

Read full description

NEURESCUE operates in the emergency medical market, targeting hospitals, emergency medical services (EMS), and other healthcare providers who deal with cardiac arrest cases. The device is particularly useful for emergency room doctors, paramedics, and other first responders who need to act quickly to save lives.

The business model of NEURESCUE revolves around the sale of its proprietary medical device to healthcare institutions. The company generates revenue through direct sales of the NEURESCUE device, as well as potential recurring revenue from the sale of disposable components and maintenance services. By providing a life-saving tool that is easy to use and highly effective, NEURESCUE aims to establish itself as a critical player in the emergency medical equipment market.

In summary, NEURESCUE is a medical device company that offers a groundbreaking solution for improving outcomes in cardiac arrest cases. By increasing blood flow to vital organs during CPR, the NEURESCUE device enhances the chances of patient survival and recovery. The company serves healthcare providers in the emergency medical field and generates revenue through the sale of its innovative device and related services.

Source: Dealroom company data

At a glance

Founded
2014
Headquarters
Copenhagen, Denmark
Sector
Biotech & Life Sciences

Latest news

Press, funding announcements and product moves mentioning Neurescue.

See all news

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • European Innovation Council

Series A1 investor entered at this stage

  • West Hill Capital
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇩🇰 Denmark75%
🇩🇪 Germany12.5%
🇬🇧 United Kingdom6.3%
🇸🇪 Sweden6.3%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neurescue on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neurescue on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.